As reviewed above, these findings indicate that DOK2 could be associated with infiltrating immune cells in the leukemia microenvironment and render poor prognosis as mediated by specific immune cell infiltration, which is anticipated to be a new immune-related therapeutic target in AML. This evidence concerns the gene DOK2 and leukemia.